神經系統

互動

雖然ABEM（Associação Brasileira de Esclerose Múltipla——巴西多發性硬化症協會）並不直接參與藥品定價決策——在巴西，此類決策由CMED（Câmara de Regulação do Mercado de Medicamentos——藥品市場監管委員會）負責——但該組織積極參與有關治療獲取、可及性及可持續性的公共與機構討論，為多發性硬化症患者及其……

互動

閱讀原文引述

南非多發性硬化症協會（MSSA）代表患者利益，倡導獲得負擔得起的有效多發性硬化症治療方案，並在政策、藥物獲取及報銷討論中傳達患者聲音。雖然MSSA並不制定或談判藥物價格，但我們與監管機構、政策制定者及諮詢機構合作，強調定價及藥物獲取決策對多發性硬化症患者的實際影響，尤其是在南非及更廣泛的非洲背景下。

Multiple Sclerosis South Africa (MSSA) represents patient interests by advocating for access to affordable, effective MS treatments and by contributing the patient voice to policy, access, and reimbursement discussions. While MSSA does not set or negotiate drug prices, we engage with regulators, policymakers, and advisory bodies to highlight the real-world impact of pricing and access decisions on people living with MS, particularly in a South African and broader African context. Our input is informed by lived experience, patient-reported challenges, and international collaboration through global MS networks, ensuring that patient needs, equity, and sustainability are considered in decision-making processes.

行動與倡議

閱讀原文引述

當出現ASM（抗癲癇藥物）短缺時，我們會動員社群，並支持為癲癇患者的藥物進行價格監管。

We rally our community when there are ASM shortages and to support price regulations for medication for patients with epilepsy.

行動與倡議

閱讀原文引述

在智利，多發性硬化症（MS）[Esclerosis Múltiple – Multiple Sclerosis] 的藥物透過 GES [Garantías Explícitas en Salud – 明確健康保障計劃] 分發，該計劃規定了福利套餐的價值。

En Chile, los medicamentos de la EM se entregan a través del GES, el cual define un valor de las canastas.